# Nervgen Pharma Corp.: financial statements, quarterly

NGEN · Nasdaq · CIK 1751912 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ngen.md) · [Financials](/companies/ngen/financials.md) · [Filings](/companies/ngen/filings.md) · [Insiders](/companies/ngen/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ngen/financials.md?period=annual).

## Balance sheet

| Line item | Unit | period not labelled (2023-12-31) | period not labelled (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: |
| Cash and equivalents | $m | [11.7](/filings/0001104659-26-037357.md) | [17.3](/filings/0001104659-26-037357.md) | [22.1](/filings/0001104659-26-037357.md) |
| Current assets | $m | not reported | [19.0](/filings/0001104659-26-037357.md) | [22.8](/filings/0001104659-26-037357.md) |
| Total assets | $m | not reported | [19.5](/filings/0001104659-26-037357.md) | [23.2](/filings/0001104659-26-037357.md) |
| Current liabilities | $m | not reported | [16.9](/filings/0001104659-26-037357.md) | [19.7](/filings/0001104659-26-037357.md) |
| Total liabilities | $m | not reported | [16.9](/filings/0001104659-26-037357.md) | [19.7](/filings/0001104659-26-037357.md) |
| Shareholders' equity | $m | [(2.0)](/filings/0001104659-26-037357.md) | [2.6](/filings/0001104659-26-037357.md) | [3.5](/filings/0001104659-26-037357.md) |

- Cash and equivalents: ifrs-full:CashAndCashEquivalents
- Current assets: ifrs-full:CurrentAssets
- Total assets: ifrs-full:Assets
- Current liabilities: ifrs-full:CurrentLiabilities
- Total liabilities: ifrs-full:Liabilities
- Shareholders' equity: ifrs-full:Equity

Shares outstanding: 79,649,257 at 2025-12-31, from the cover of the [40-F filed 2026-03-31](/filings/0001104659-26-037357.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.